cardiomyocytes Archives

What is the Most Predictive Cardiac Cell Model? FDA Publication Confirms COR.4U By Axiogenesis

November 11, 2016 By Cade Hildreth (CEO) Leave a Comment

Two recent peer-reviewed publications underline the predictive value of Axiogenesis Cor.4U iPSC-derived cardiomyocytes (iPSC-CMs).

There was a publication earlier this year by Astra Zeneca researchers that resulted in a somewhat negative perception (mostly by iPS cell skeptics) of iPSC-derived cells. The predictive value of iPSCs was questioned, with the abstract stating, “iCell^® cardiomyocytes have limited value as an integrated QT/TdP assay, highlighting the urgent need for improved experimental alternatives that may offer an accurate integrated cardiomyocyte safety model for supporting the development of new drugs without QT/TdP effects.” [Read more…]

Axiogenesis and Metrion Biosciences to Develop Human iPSC-derived Cardiomyocytes and Neurons

November 7, 2016 By Cade Hildreth (CEO) Leave a Comment

Axiogenesis announced today that it will be collaborating with Metrion Biosciences to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately predict cardiac arrhythmia and neuronal risk. Metrion Biosciences a UK-based contract research organization (CRO) that is best known as an ion channel specialist.

Through this strategic partnership, Axiogenesis continues to strengthen its position within the iPS cell marketplace as a leading provider of cell-based solutions to facilitating drug discovery, safety, and toxicology applications. To learn more, see the full press release, included below with permission from Axiogenesis.

Axiogenesis is a fascinating company specializing in the development of induced pluripotent stem cells (iPSCs) and tissue types. It is the second largest iPSC company in the world after Cellular Dynamics International (CDI), in Madison, Wisconsin.

Axiogenesis was also the first European company to license and adopt Yamanaka’s iPSC technology in 2010. The company now specializes in human induced pluripotent stem cell (hiPSC) products, including in vitro models of healthy and diseased cell types and tissues.

Pluriomics Awarded €3.2M to Advance Cardiovascular Drug Discovery – Reducing Time, Cost, & Late Stage Attrition of Drug Candidates

June 16, 2016 By Cade Hildreth (CEO) Leave a Comment

Pluriomics is a Dutch company that specializes in the “production and industrialization of high-quality, fully functional hiPS cells-derived cardiovascular cell types and on the development and realization of electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology, toxicology testing and efficacy screening.”

In news released today, the company announced that it will receive a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery.

The company also announced last month that it will lead a €2.0 million Eurostars consortium for the development of a novel in vitro organ-on-a-chip heart failure model for drug discovery and development.

To learn more about the €3.2M grant under the Horizon 2020 SME instrument programme, read the full press release below, printed with permission from Celine Hechard, PhD, VP Business Development & Marketing at Pluriomics. [Read more…]

Two recent peer-reviewed publications underline the predictive value of Axiogenesis Cor.4U iPSC-derived cardiomyocytes (iPSC-CMs).

BioInformant's World-Class Clients